SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (date of earliest event reported): January 21, 2009
BioTime,
Inc.
(Exact
name of registrant as specified in its charter)
|
California
|
1-12830
|
94-3127919
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
1301
Harbor Bay Parkway
Alameda,
California 94502
(Address
of principal executive offices)
(510)
521-3390
(Registrant's
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Statements made in this Report that
are not historical facts may constitute forward-looking statements that are
subject to risks and uncertainties that could cause actual results to differ
materially from those discussed. Such risks and uncertainties include
but are not limited to those discussed in this report and in our other reports
filed with the Securities and Exchange Commission. Words such as “expects,”
“may,” “will,” “anticipates,” “intends,” “plans,” “believes,” “seeks,”
“estimates,” and similar expressions identify forward-looking
statements.
Section
7 - Regulation FD
Item
7.01 - Regulation FD Disclosure
Section
9 - Financial Statements and Exhibits
Item
9.01 - Financial Statements and Exhibits
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release dated January 21, 2009
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
BIOTIME,
INC.
|
|
|
Date: January
21, 2009
|
By /s/ Steven
A. Seinberg
|
|
Chief
Financial Officer
|
|
3
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release dated January 21, 2009
|
|
Exhibit
99.1
|
BioTime,
Inc.
|
1301
Harbor Bay Parkway
|
|
|
Alameda,
CA 94502
|
||
|
Tel:
510-521-3390
|
||
|
Fax:
510-521-3389
|
||
|
www.biotimeinc.com
|
||
|
www.embryome.com
|
BioTime
Launches New Stem Cell Lines in Anticipation of
President
Obama’s Removal of Restrictions on Federal Funding of
Embryonic
Stem Cell Research
New
Cell Line Products to be Presented at Stem Cells World
Conference
ALAMEDA, CA, January 21, 2009 – BioTime, Inc. (OTCBB: BTIM)
Chief Executive Officer Michael West, Ph.D., will deliver a presentation on
January 21, 2009 at the Select Biosciences Stem
Cells World Congress meeting in Palm Springs, California. Dr.
West’s presentation is titled “Embryomics: High Throughput Generation and
Mapping of Embryonic Progenitors.”
This
year’s conference will focus on new technologies in stem cell research and
development, including the basic biology, medical applications, regulation, and
business of stem cells. Dr. West’s presentation will include a description of
BioTime’s stem cell research programs and near-term stem cell
products being marketed to the research community.
Dr. West
will announce the launch of 11 new cell line products and present data on their
unique properties and potential utility in regenerative medicine. The new cell
lines show markers of neural, muscle, vascular, and cartilage progenitors, as
well as other properties of interest to the medical research community. The
cells will initially be marketed to universities and pharmaceutical companies
for use in research programs focused on developing new cell-based therapies for
neurodegenerative disease, muscular dystrophy, heart disease, cancer, and
arthritis, as well as other potential applications in the emerging field of
regenerative medicine. Information about these cell lines is now available
online at www.embryome.com, and
the cells themselves are available for purchase for research purposes only,
through the same website.
President
Barack Obama has indicated that he will rescind President Bush’s August 9, 2001
restrictions on federal funding of human embryonic stem cell research. Since
2001, hundreds of new embryonic stem cell lines have been made, including 72
novel cell types isolated by BioTime scientists, that will not be eligible for
use in federally-funded research to fashion new medical therapies until the
restrictions imposed by the Bush Administration are rescinded.
“We look
forward to a change in policy that allows federally-funded researchers to
utilize human embryonic stem cells generated since 2001,” said Michael West,
Ph.D., BioTime’s CEO. “We have scaled up inventory for the launch of these new
cell lines and plan on launching additional similar products in the
future.”
About
BioTime, Inc.:
BioTime,
headquartered in Alameda, California, develops blood plasma volume expanders,
blood replacement solutions for hypothermic (low temperature) surgery, organ
preservation solutions, and technology for use in surgery, emergency trauma
treatment and other applications. BioTime's lead product Hextend is manufactured
and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ
CheilJedang Corp. under exclusive licensing agreements.
BioTime operates in the field of regenerative medicine
through its wholly owned subsidiary Embryome
Sciences, Inc. where it
is developing new medical and research products
using embryonic stem cell technology. Additional information about BioTime
can be found on the web at www.biotimeinc.com. Hextend®, PentaLyte®, HetaCool®, EmbryomicsTM, ESpyTM, and ESpanTM, are trademarks of BioTime,
Inc.
Forward-Looking
Statements
Statements
pertaining to future financial and/or operating results, future growth in
research, technology, clinical development and potential opportunities for the
company and its subsidiary, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by management
constitute forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words such as
“will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,”) should also
be considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks inherent
in the development and/or commercialization of potential products, uncertainty
in the results of clinical trials or regulatory approvals, need and ability to
obtain future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with the
many uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities and
Exchange Commission filings. The company disclaims any intent or obligation to
update these forward-looking statements.
Contact:
BioTime,
Inc.
Judith
Segall
jsegall@biotimemail.com
510-521-3390,
Ext. 301
To
receive ongoing BioTime corporate communications, please click on the following
link to join our email alert list: http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0